Crossmark

A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections

Crossref DOI link: https://doi.org/10.1186/s12967-019-2040-y

Published Online: 2019-08-23

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Esposito, Susanna https://orcid.org/0000-0003-4103-2837
Bianchini, Sonia

Bosis, Samantha

Tagliabue, Claudia

Coro, Ilaria

Argentiero, Alberto

Principi, Nicola
Funding

Funding for this research was provided by:

World Association of Infectious Diseases and Immunological Disorders grant (WAidid2016_06)
License Information

Text and Data Mining valid from 2019-08-23

Version of Record valid from 2019-08-23
More Information

Article History

Received: 13 May 2019

Accepted: 18 August 2019

First Online: 23 August 2019

Ethics approval and consent to participate

: This study was approved by the Ethics Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy (no. 418_2016bis), and written informed consent was obtained from all the participants’ parents or legal guardians.

: Written informed consent was obtained from all the participants’ parents or legal guardians.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below